Research and Markets has announced the addition of the "Blepharitis - Pipeline Review, H2 2016" drug pipelines to their offering.
'Blepharitis - Pipeline Review, H2 2016'; Blepharitis pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.
Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.
'Blepharitis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 1 and 2 respectively.
Key Topics Covered:
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/btb9ms/blepharitis
Related Topics: Optical
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006070/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.